AU
UK
CA
NZ
IND
US
Why LIXTE Biotechnology Holdings (NASDAQ: LIXT) Stock Jumped Today
The Persistent Shadow of Consolidation Risk
There are moments in biotech when the market's verdict arrives swiftly and without ambiguity. Tuesday was one such moment for Edgewise Therapeutics, a Boulder-based clinical-stage company quietly building a case for itself in the fiercely competitive muscular dystrophy space. An 18% single-session gain is …
There is a particular kind of disappointment in biotech that is harder to absorb than a failed clinical trial. A trial failure, however painful, belongs to science. What happened to Fulcrum Therapeutics is different. Pociredir worked. The fetal hemoglobin numbers moved. There were no …
When a biotech company's board formally lists an "orderly wind-down" as one of its strategic options, the market tends to take that language atFace Value. On Tuesday, investors in Jasper Therapeutics (Nasdaq: JSPR) did exactly that, sending shares down 36% to $0.53 in a …
The Misalignment BetweenRevenuePerformance and Stock Reaction
The Paradox of Abundance
The Paradox of Strength and Repricing
The Machinery of Member Retention
The Resurgence of Geopolitical Risk Premium
Please wait processing your request...